See more : Silk Logistics Holdings Limited (SLH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Gland Pharma Limited (GLAND.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gland Pharma Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Public Joint-Stock Company OR (ORUP.ME) Income Statement Analysis – Financial Results
- Future Data Group Limited (8229.HK) Income Statement Analysis – Financial Results
- Waitr Holdings Inc. (ASAPQ) Income Statement Analysis – Financial Results
- Compagnie Financière de Neufcour S.A. (MLNEU.BR) Income Statement Analysis – Financial Results
- Clean Energy Technologies, Inc. (CETY) Income Statement Analysis – Financial Results
Gland Pharma Limited (GLAND.BO)
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 56.42B | 35.92B | 43.84B | 34.24B | 25.72B | 19.93B | 15.80B |
| Cost of Revenue | 42.65B | 16.85B | 21.09B | 14.92B | 11.02B | 8.57B | 6.61B |
| Gross Profit | 13.77B | 19.06B | 22.75B | 19.32B | 14.70B | 11.36B | 9.19B |
| Gross Profit Ratio | 24.41% | 53.08% | 51.89% | 56.42% | 57.15% | 57.00% | 58.18% |
| Research & Development | 320.32M | 403.77M | 426.56M | 321.99M | 228.75M | 207.17M | 189.12M |
| General & Administrative | 1.32B | 485.32M | 301.60M | 162.70M | 139.51M | 88.63M | 503.72M |
| Selling & Marketing | 374.64M | 270.32M | 409.81M | 366.94M | 170.76M | 138.78M | 99.31M |
| SG&A | 1.70B | 755.64M | 711.41M | 529.64M | 310.27M | 227.41M | 603.03M |
| Other Expenses | 1.84B | 10.53M | 15.99M | 82.77M | 9.78M | 5.76M | 2.82M |
| Operating Expenses | 3.86B | 10.20B | 8.75B | 7.28B | 6.07B | 5.22B | 4.61B |
| Cost & Expenses | 46.51B | 27.05B | 29.84B | 22.20B | 17.09B | 13.79B | 11.22B |
| Interest Income | 1.51B | 1.79B | 1.39B | 859.49M | 514.86M | 433.13M | 271.68M |
| Interest Expense | 262.00M | 62.87M | 34.02M | 29.11M | 62.51M | 26.17M | 32.48M |
| Depreciation & Amortization | 3.45B | 1.47B | 1.10B | 987.80M | 945.87M | 821.20M | 783.68M |
| EBITDA | 14.99B | 12.09B | 17.34B | 14.37B | 10.95B | 7.72B | 5.84B |
| EBITDA Ratio | 26.57% | 35.35% | 39.42% | 41.97% | 41.91% | 39.15% | 36.98% |
| Operating Income | 9.91B | 8.88B | 14.03B | 11.79B | 8.06B | 5.73B | 4.18B |
| Operating Income Ratio | 17.56% | 24.72% | 32.01% | 34.43% | 31.33% | 28.77% | 26.44% |
| Total Other Income/Expenses | 1.42B | 1.68B | 2.18B | 1.31B | 1.30B | 724.23M | 432.65M |
| Income Before Tax | 11.33B | 10.55B | 16.19B | 13.35B | 9.93B | 6.86B | 5.01B |
| Income Before Tax Ratio | 20.07% | 29.36% | 36.92% | 38.99% | 38.61% | 34.43% | 31.74% |
| Income Tax Expense | 3.60B | 2.74B | 4.07B | 3.38B | 2.20B | 2.34B | 1.80B |
| Net Income | 7.72B | 7.81B | 12.12B | 9.97B | 7.73B | 4.52B | 3.21B |
| Net Income Ratio | 13.69% | 21.74% | 27.64% | 29.12% | 30.05% | 22.67% | 20.32% |
| EPS | 46.90 | 47.44 | 73.81 | 63.07 | 49.88 | 27.67 | 19.66 |
| EPS Diluted | 46.89 | 47.43 | 73.64 | 62.99 | 49.88 | 27.67 | 19.66 |
| Weighted Avg Shares Out | 164.70M | 164.64M | 164.15M | 158.08M | 154.95M | 163.28M | 163.28M |
| Weighted Avg Shares Out (Dil) | 164.74M | 164.68M | 164.54M | 158.28M | 154.95M | 163.28M | 163.28M |
Source: https://incomestatements.info
Category: Stock Reports